Laki- laki Perempuan
KESIMPULAN DAN SARAN Kesimpulan
Kesimpulan
Berdasarkan hasil penelitian ini dapat diambil kesimpulan sebagai berikut :
1. Dijumpai adanya hubungan yang bermakna antara antibodi anti
Epsteinbarr virus (EBNA-1) dengan karsinoma nasofaring pada
pasien etnis Batak.
2. Gambaran histopatologi yang diteliti pada penelitian ini yang
terbanyak adalah karsinoma nasofaring yang undifferensiasi
(57,7%).
3. Karsinoma nasofaring pada penelitian ini terbanyak pada usia
30-49 tahun.
4. Tidak dijumpai adanya hubungan yang bermakna keberadaan
Saran
1. Meskipun sudah signifikan bahwa infeksi virus epstein-barr sebagai
penyebab karsinoma nasofaring tetapi perlu dilakukan pemeriksaan
lagi untuk mengetahui penyebab pasti bahwa infeksi virus epstein-barr
mengakibatkan karsinoma nasofaring dengan melakukan pemeriksaan
PCR atau dengan binatang percobaan.
2. Semua pasien yang diduga karsinoma nasofaring dilakukan
pemeriksaan EBNA-1, karena dapat membantu menguatkan diagnosa
karsinoma nasofaring, di mana ini berguna untuk mengetahui bahwa
karsinoma tersebut disebabkan oleh virus epsteinbarr atau karena
KEPUSTAKAAN
Adnan A,1996, Beberapa Aspek karsinoma nasofaring bag. THT FK USU RSUP.H.Adam Malik Medan,Tesis.
Allan hildesheim et al,2002, Association of HLA Class I and II Alleles and Extended Haplotypes With Nasopharyngeal Carcinoma in Taiwan . JNCI Cancer Sperctrum, vol.94, No.23, 1780-1789.
Armstrong R.W., Imrey P.B., Lyc M.S., Armstrong M.J., Yu M.C., Sani S., 2000,
Nasopharyngeal carcinoma in Malaysian Chinese: occupational
exposures to particles, formaldhyde and heat. International Journal of Epidemiology.29:991-8.
Asroel H.A,2002, Penatalaksanaan Radioterapi pada Karsinoma Nasofaring, Fakultas Kedokteran Bagian Tenggorokan Hidung dan Telinga. Universitas Sumatera Utara. Digitized by USU digital library.
Bouvier G., Hergenhahn M., Polack A., Bornkamm G.W., 1995, The G.de and Bartsch H, Characterization of macromolecular lignins as Epstein – Barr virus inducer in foodstuff associated with nasopharyngeal carcinoma risk.. 16: 1879-1885
Bochkarev et al, 1996 Se muestra la estructura cristalina del EBNA1 unida al ADN. La región azul representa la parte central de la proteína, con los anillos dorados que representan las regiones adyacentes heleicodales alfa , que también contactan con el ADN. Cell 84:791
Bambang S.S. 1997, Asean Otorhinolaryngology- Head and Neck Surgery Journal Vol.1 No.1..W.H.O classification of the nasopharyngeal carcinoma in North Central Java.
Beasley P.In Scott Brown’s Otolaryngology Basic science1978,5 th Ed.Butterworth, London, Boston, Dublin, Singapora, Sidney, Toronto, Melborne, ,245-271, Anatomy of the pharynx and oesophagus.
Chan A.T.C., Teo P.M.L., Johnson P.J., 2002, Nasopharyngeal carcinoma. Annals of Oncology 13: 1007-1015.
Curran .A, Laverty F.S, Campbell D, Macdiarmid J and Wilson J.B. 2006
Damania, B. 2004. Human Gammanherpesviruses: EBV and HHV-8. Fields Virology, 4th edition, Chapters 74,75 and 82. Nature Rev Microbiol 2:656
Djojodiharjo B, 1986, Karsinoma Nasofaring Pada Anak. Dalam : Kumpulan Naskah Ilmiah, Konas VIII Perhati, Ujung Pandang, 6-9 Juli, hal. 110-115
Fachiroh J., Schouten T., Hariwiyanto B., Paramita D.K., Harijadi A., Haryana S.M., Ng. Mun.H., and Middeldorp J.M. 2004. Molecular Diversity of Epstein-Barr Virus IgG and IgA antibody Responses in Nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European Subjects.JID. 190 : 53-62
Gulley .M.L. 2001 Molecular Diagnosis of Epstein-Barr Virus Related Diseases. Journal of Molecular Diagnostics,; 3 (1).
Henle, G. and Henle, W. Epstein Barr virus specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinomal. Int J cancer 17: 1, 1976.
Infectious mononucleosis and Epstein–Barr virus,2004 Eleni-Kyriaki. Reviews in Molecular Medicine ; http:// www.expertreviews.org.
Huang D.P., Ho, J.H., Henle, W and Henle, G. Demonstration of Epstein-Barr Virus associated nuclear antigen in nasopharyngeal carcinoma from fresh biopsies. Int. J Cancer 14: 580, 1974.
James D.Watson,et al, Molecular Biology of The Gene,fourth edition. Some DNA Repair Enzymes Recognize and Reverse Specific Products of DNA Damage : Photolyase and 06- Methylguanine Methyltrasnferase, page 346.
Krishna S.M., James S, Kattoor J and Balaram P, 2004. Serum EBV DNA as a Biomarker in Primary Nasopharyngeal Carcinoma of Indian Origin. Jpn J Clin Oncol. 34 (6) : 307-311
Longnecker, 1998 R Pathogenesis of Epstein-Barr virus. In Human Tumor Viruses. (McCance, D., ed),pp. 133 – 174, ASM Press .
Lutan R. Blood- Groups and Nasopharyngeal Carcinoma, Departement of otolarynglogy North Sumatra University School of Medicine Dr. Pirngadi Hospital, Medan – Indonesia, 1988.
Lukito J.S., Patologi karsinoma nasofaring, Majalah Kedokteran Nusantara, Vol.XXXIV, No.2-3, FK USU Medan, Juli- September,1994, 606-611.
Li P, Ai P, Chen L, Yang Y,Li Z, Zhang H. Analysis on clinical data of 677 death cases with nasopharyngeal carcinoma. Lin Chuang Er Bi Yan Hou Ke
Ming Cheng H., Ting Foong Y., Kook Sam C., Prasad U and Dillner J., 1991Epstein-Barr Virus Nuclear Antigen 1 Linear Epitopes That Are Reactive with Immunglobulin A (IgA) or IgG in Sera from Nasopharyngeal Carcinoma Patients or from Healthy Donors.Journal of Clinical Microbiology . 29:2180-2186.
Myers EN, Suen JY,1989 Cancer of the head and neck. 2nd ed. New York : Churchill Livngstone, h .495-507.
Mungerson M.S., Ikeda M., Lev.L., Longnecker R., and Portis T., 2003. Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein-Barr virus (EBV) – associated diseases. JAC, 200;, 52: 152-154.
Munir D. Beberapa Aspek Karsinoma Nasofaring pada Suku Batak di medan dan sekitarnya. The Journal Of Medical School University of Sumatera Utara, 2006; Vol.39 (3) : 223 – 226.
McKee R.James, Gene Information,Biochemistry, The Molecular Basis of Life, Third Edition, Chapter 18, page. 654.
Munz C., Bickham L.K., Subklewe M.,Tsang L.M., Charoudi A., Kurilla G.M., et al . 2000. Human CD4 T lymfocytes Consistently Respond to Latent Epstein-barr Virus Nuclear antigen 1. The Journal of Experimental Medicine 2000 ; 191:1-29.
Oberender,H.,Nowak,R., Donvier,B.E., Venka,V., Tetrin,W. and Kankel, N. EBV specific antibodies in patients with nasopharyngeal carcinoma. Laryngorhinologie 68: 181, 1989.
Paul G.Murray, Lawrence S. Young, 2003. Epstein-Barr virus infection: basis of malignancy and potential for therapy. Cambridge University Press ISSN, 2001; 1462-3994
Portis T., Ikeda M., Longnecker R., 2004 Epstein-Barr virus LMP2A : regulating cellular ubiquitination processes for maintenance of viral latency?,TRENDS in Immunology vol.8
Ralf D. Hess. 2004. Routine Epstein – Barr Virus Diagnostic from the Laboratory Prespective : Still Challenging after 35 Years. Minireview. JCM 42:3381-3387.
Simanjuntak A, 2002, Tesis. Distribusi Golongan Darah Penderita Karsinoma Nasofaring Dan Non Karsinoma Nasofaring Menurut Jenis Kelamin, FK USU, Medan.
Stevens S.J. C, Verkuijlen S.AW.M., Hariwiyanto B., Harijadi, Fachiroh J., Paramita.D.K., et al. , 2005. Diagnostic Value of Measuring Epstein – Barr Virus (EBV) DNA Load and Carcinoma-Specific Viral mRNA in Relation to Anti-EBV Immunoglobulin A (IgA) and IgG Antibody Levels in Blood of Nasopharyngeal Carcinoma Patients in Indonesia. Journal of Clinical Microbiology 43 : 3066-3073.
Soetjipto D,1989 Karsinoma nasofaring. Dalam : Tumor telinga, hidung dan tenggorok. Diagnosis dan penatalaksanaan, Balai Penerbit FK UI, Jakarta,71-84.
Thomson M.P., Kurzrock R., 2004. Epstein-Barr Virus and Cancer. Clinical Cancer Research 10 : 803-821.
Watson D.James et al, 1988. The Genetic Basis of cancer, Molecular Biology of The Gene, Fouth edition, Chapter 26, hal. 1042-1043
Xu J.,Ahmad A, D’Addario M., Knafo L., Jones J.F., Prasad U., Dolcetti R., Vaccher E., Menezes J., 2000 Analysis Significance Anti-Latent Membrane Protein-1 Antibodies in the Sera of Patients with EBV- Associated Diseases. The American Association of Immunologists..
Yang X., Diehl S., Pfeiffer R., Chen C.J., Hsu W.L., Dosemeici M.,et al., 2005. Evaluation of Risk Factors for Nasopharyngeal Carcinoma in High-Risk Nasopharyngeal Carcinoma Families in Taiwan, Cancer Research 14: 900-905.
Zachreni I., Delyuzar, 1999,Tesis. Hubungan Virus Epstein Barr dengan Karsinoma Nasofaring secara Immunohistokimia, FK USU, Medan.
Lampiran 1. Data pasien penderita karsinoma nasofaring yang diperiksa keberadaan EBNA-1 NO Pasien Kadar EBNA-1 (U/ml) Jenis NPC Jenis kelamin Umur (tahun) 1 D32 81,9 UC PR 39 2 D33 57,4 UC LK 34 3 D34 40,1 UC PR 60 4 D35 44,9 SCC LK 45 5 D36 0 UC PR 43 6 D37 33,3 UC LK 36 7 D38 0 NKC LK 70 8 D39 33,6 SCC LK 60 9 D40 22,5 NKC LK 50 10 D41 64,7 SCC LK 70 11 D42 144,4 UC PR 38 12 D43 82,1 NKC PR 46 13 D44 57,5 SCC LK 60 14 D45 40 UC PR 45 15 D46 33,0 UC LK 63 16 D47 7,9 UC PR 37 17 D48 93,3 UC PR 40 18 D49 0 UC LK 59 19 D50 54,1 SCC LK 53 20 D51 20,9 UC LK 35 21 D52 103,7 UC LK 47 22 D53 48,9 UC PR 34 23 D54 45,7 SCC LK 42 24 D55 54,1 SCC LK 37 25 D56 0 SCC LK 47 26 D57 56,7 UC LK 57 Catatan :
Konsentrasi >12 U/ml : Positive Konsentrasi 8-12 U/ml : boderline Konsentrasi < 8 U/ml : Negative
Lampiran 2. Data kontrol yang diperiksa keberadaan EBNA-1.
No Kontrol Konsentrasi EBNA-1 Umur (tahun) Jenis Kelamin
1 K4 0 66 Perempuan 2 K5 0 59 Laki-laki 3 K6 0 62 Perempuan 4 K7 0 67 Perempuan 5 K8 0 71 Perempuan 6 K10 0 42 Perempuan 7 K11 0 42 Perempuan 8 K18 0 43 Laki-laki 9 K27 0 24 Perempuan 10 K28 0 23 Perempuan 11 K31 0 45 Perempuan 12 K41 0 40 Perempuan 13 K51 0 35 Laki-laki 14 K53 0 37 Laki-laki 15 K54 0 40 Laki-laki 16 K55 0 55 Laki-laki 17 K63 0 31 Laki-laki 18 K67 0 33 Laki-laki 19 K85 0 31 Laki-laki 20 K89 0 63 Laki-laki
EBVKEL * KLPK Crosstabulation 5 20 25 19.2% 100.0% 54.3% 21 0 21 80.8% .0% 45.7% 26 20 46 100.0% 100.0% 100.0% Count % within KLPK Count % within KLPK Count % within KLPK negatif positif EBVKEL Total kasus kontrol KLPK Total Chi-Square Tests 29.723b 1 .000 26.557 1 .000 37.965 1 .000 .000 .000 29.077 1 .000 46 Pearson Chi-Square Continuity Correctiona Likelihood Ratio Fisher's Exact Test Linear-by-Linear Association N of Valid Cases Value df Asymp. Sig. (2-sided) Exact Sig. (2-sided) Exact Sig. (1-sided)
Computed only for a 2x2 table a.
0 cells (.0%) have expected count less than 5. The minimum expected count is 9.13. b. HISTO 3 11.5 11.5 11.5 8 30.8 30.8 42.3 15 57.7 57.7 100.0 26 100.0 100.0 NKC SCC UC Total Valid
Frequency Percent Valid Percent
Cumulative Percent Descriptive Statistics 26 ,0 144,4 46,950 34,8355 26 EBNA Valid N (listwise)
Lampiran 4